Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Assess Cancer in Ovarian Tumors With Biomarkers.
NCT00436189 · View on ClinicalTrials.gov ↗
Study Summary
Purpose The OvaRI assay clinical trial is directed at evaluating a novel proteomics-based blood test. This test is for a physician to use towards differentiating benign from malignant ovarian tumors prior to surgical intervention. Tools that can better triage women with an ovarian tumor are needed. It has been shown that women with ovarian cancer who are referred to gynecologic oncologists have better outcomes. The primary objective of this study is to demonstrate that the OvaRl assay (test) improves the preoperative identification of ovarian cancer in patients with a ovarian tumor.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
Study Locations (18)
Arizona
- Women's Health Research — Phoenix
- Precision Trials — Phoenix
California
- Gynecologic Oncology Associates — Newport Beach
- North Coast Women's Care Medical Group Inc — Vista
Connecticut
- Farmington Obstetrics and Gynecology Group — Avon
- The GYN Center for Women's Health — Waterbury
Florida
- Florida Hospital Cancer Institute — Orlando
- OB/GYN Specialists of the Palm Beaches — West Palm Beach
Texas
- SWRCC — Austin
- UT South Western Medical Center at Dallas — Dallas
Alabama
- Clinical Research Consultants — Hoover
Kentucky
- University of Kentucky - Whitney Facility — Lexington
Maine
- Maine Medical Center — Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-04 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00436189
The ClinicalTrials.gov registry entry for NCT00436189 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ciphergen Biosystems, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Ovarian Tumor appearing as the primary indexed condition, and to 1 intervention — of which Blood Draw is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00436189 reports 18 study locations spanning 13 distinct geographic areas — top geographies include Arizona, California, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00436189 about?
NCT00436189 is a clinical study titled "Assess Cancer in Ovarian Tumors With Biomarkers.". Purpose The OvaRI assay clinical trial is directed at evaluating a novel proteomics-based blood test. This test is for a physician to use towards differentiating benign from malignant ovarian tumors prior to surgical intervention. Tools that can better triage women with an ovarian tumor are needed....
What is the current status of trial NCT00436189?
This trial is currently completed. It is a NA study. The enrollment target is 1,000 participants. The study started on 2007-02. Estimated completion is 2008-04.
What conditions does trial NCT00436189 study?
This clinical trial studies the following conditions: Ovarian Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00436189?
The interventions under investigation include: Blood Draw (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00436189?
This trial is sponsored by Ciphergen Biosystems, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00436189 being conducted?
This trial has 18 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.